<--- Back to Details
First PageDocument Content
Pharmacology / Drug safety / AstraZeneca / FluMist / Influenza vaccine / Influenza / Pharmacovigilance / Safety / Medicine / Vaccines / Health
Date: 2013-10-09 09:36:49
Pharmacology
Drug safety
AstraZeneca
FluMist
Influenza vaccine
Influenza
Pharmacovigilance
Safety
Medicine
Vaccines
Health

Paul-Ehrlich-Institut Public consultation paper – Review of the Variations Regulation Review of Commission Regulation (EC) No[removed]Joint Statement of the Federal Institute for Drugs and Medical Devices (BfArM),

Add to Reading List

Source URL: ec.europa.eu

Download Document from Source Website

File Size: 226,10 KB

Share Document on Facebook

Similar Documents

Dear Colleague, The Bill & Melinda Gates Foundation is excited to announce the opening of a new Grand Challenges grant opportunity: Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Developmen

DocID: 1v6ON - View Document

Southeast Asian J Trop Med Public Health IMPACT OF NATIONAL INFLUENZA VACCINE CAMPAIGN ON RESPIRATORY ILLNESS IN THAILAND, Patummal Silaporn1 and Suchada Jiamsiri2

DocID: 1uCtR - View Document

CAMPUS HEALTH CENTER | 5200 Anthony Wayne Drive, Suite 115, Detroit, MI 48202 | (QUADRIVALENT INACTIVATED INFLUENZA VACCINE CONSENT NAME: _________________________________________ DOB: __________

DocID: 1uu43 - View Document

Questions and Answers Vaccine effectiveness estimates for seasonal influenza vaccines February.

DocID: 1tpnT - View Document

HPAI and Vaccine Use The outbreak of highly pathogenic avian influenza (HPAI) H5 in spring 2015 was the worst animal disease outbreak in U.S. history. This disease is extremely deadly to chickens and turkeys and caused s

DocID: 1tiKr - View Document